Trial Profile
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Lisaftoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Hairy cell leukaemia; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Ascentage Pharma
- 27 Nov 2023 Planned End Date changed from 15 Feb 2023 to 15 Feb 2025.
- 27 Nov 2023 Planned primary completion date changed from 15 Sep 2022 to 15 Sep 2024.
- 19 Apr 2023 Results (n=52), published in the Clinical Cancer Research